8-K: Cassava Sciences Faces DOJ Indictment and SEC Scrutiny Over Alzheimer's Drug Research

Cassava Sciences is under investigation by the DOJ and SEC, with a recent indictment of a former collaborator for alleged research fraud, prompting an internal investigation and supplemental disclosures regarding a Phase 2b study.

Summary

• Cassava Sciences is currently cooperating with the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) regarding ongoing investigations into the company and two senior employees.
• The SEC recently provided Cassava with new information related to its Phase 2b study of simufilam in Alzheimer's disease, leading to an internal investigation by an Ad Hoc Investigation Committee of independent directors.
• The DOJ has indicted Dr. Hoau-Yan Wang, a former scientific collaborator, for allegedly submitting false and fraudulent grant applications to the NIH regarding simufilam research.
• Dr. Wang's research, including bioanalysis for the Phase 2b study, is now under scrutiny, and Cassava has terminated its consulting relationship with him.
• Cassava is supplementing its prior disclosures regarding the Phase 2b study, revealing that certain statistical information could have unblinded Dr. Wang to some study participants.
• The company is also reporting post hoc statistical analysis of CANTAB cognitive outcome measures from the Phase 2b study, which had significant participant exclusions.
• The Phase 2b study excluded approximately 42% of participants from the episodic memory analysis due to baseline scores and other factors.
• Cassava's ongoing Phase 3 clinical trials of simufilam are being conducted with independent third-party analysis, and Dr. Wang has no involvement.
• The company emphasizes that results from earlier trials may not predict future outcomes and cautions against undue reliance on forward-looking statements.

Sentiment

Score: 2

Explanation: The document reveals serious issues including a DOJ indictment, SEC investigation, and concerns about data integrity, leading to a very negative sentiment.

Positives

• Cassava is cooperating with the DOJ and SEC investigations.
• An independent committee is overseeing the internal investigation.
• The company is using independent third-party firms for analysis in Phase 3 trials.
• Dr. Wang has been terminated as a consultant and removed from the cash incentive plan.
• The company is providing supplemental disclosures to address concerns about the Phase 2b study.

Negatives

• The DOJ has indicted a former scientific collaborator for alleged research fraud.
• The SEC is investigating the company's Phase 2b study.
• The internal investigation has revealed potential unblinding of study participants in the Phase 2b study.
• Significant exclusions of participants in the Phase 2b study analysis raise concerns about the validity of the results.
• The company's past disclosures regarding the Phase 2b study are being questioned.

Risks

• The ongoing government investigations could lead to significant penalties or reputational damage.
• The internal investigation may uncover further issues with the company's research practices.
• The indictment of Dr. Wang could undermine confidence in the company's scientific data.
• The supplemental disclosures regarding the Phase 2b study may negatively impact investor confidence.
• The company's clinical trials may not yield positive results, and regulatory approval is not guaranteed.

Future Outlook

The company is continuing its Phase 3 clinical trials with independent analysis, but the outcome of these trials and the ongoing investigations are uncertain. The company cautions against relying on forward-looking statements.

Management Comments

• Cassava is cooperating with the DOJ and SEC in connection with these investigations.
• The Board has empowered an Ad Hoc Investigation Committee to direct an internal investigation.
• The company is supplementing its prior disclosures regarding the Phase 2b study.
• The company emphasizes that results from earlier trials may not predict future outcomes.

Industry Context

This announcement highlights the risks associated with clinical research and the importance of data integrity in the pharmaceutical industry. The scrutiny of Cassava's research could have broader implications for other companies developing treatments for Alzheimer's disease.

Comparison to Industry Standards

• The issues raised regarding data integrity and statistical analysis in Cassava's Phase 2b study are concerning, as they deviate from standard practices in clinical research.
• The exclusion of a significant portion of participants from the analysis is unusual and raises questions about the robustness of the results. This contrasts with companies like Biogen and Eli Lilly, which typically report results based on intention-to-treat analysis.
• The involvement of a scientific collaborator in both the research and bioanalysis, as was the case with Dr. Wang, is not a standard practice and creates a potential conflict of interest. Most companies use independent labs for bioanalysis.
• The use of post hoc analysis and the lack of statistical power in the CANTAB tests are also deviations from best practices in clinical trial design. Companies like Roche and AbbVie typically design trials with sufficient power to achieve statistical significance.

Legal Proceedings

• The company is under investigation by the DOJ and SEC.
• Dr. Hoau-Yan Wang has been indicted by the DOJ for alleged research fraud.

Related Party Transactions

• Dr. Wang received a monthly stipend of $2,000 for over a decade and was granted stock options.

Stakeholder Impact

• Shareholders face significant uncertainty due to the ongoing investigations and potential legal liabilities.
• Employees may experience job insecurity and reputational damage.
• Customers and patients may lose confidence in the company's products.
• Suppliers and creditors may face increased risk due to the company's financial instability.

Next Steps

• The internal investigation will continue.
• The company will continue to cooperate with the DOJ and SEC.
• The company will continue its Phase 3 clinical trials with independent analysis.
• The company will provide further updates as the investigations progress.

Key Dates

Keywords

Cassava Sciences, simufilam, Alzheimer's disease, DOJ, SEC, investigation, clinical trials, Phase 2b study, Dr. Hoau-Yan Wang, fraud, NIH, CANTAB, biomarkers